{"id":23865,"date":"2026-06-14T15:50:24","date_gmt":"2026-06-14T15:50:24","guid":{"rendered":"https:\/\/globalnewstoday.uk\/index.php\/2026\/06\/14\/uw-drug-trial-tests-a-glp-1-treatment-for-alcohol-addiction-knkx\/"},"modified":"2026-06-14T15:50:24","modified_gmt":"2026-06-14T15:50:24","slug":"uw-drug-trial-tests-a-glp-1-treatment-for-alcohol-addiction-knkx","status":"publish","type":"post","link":"https:\/\/globalnewstoday.uk\/index.php\/2026\/06\/14\/uw-drug-trial-tests-a-glp-1-treatment-for-alcohol-addiction-knkx\/","title":{"rendered":"UW drug trial tests a GLP-1 treatment for alcohol addiction – KNKX"},"content":{"rendered":"

Researchers at the University of Washington are joining an international drug trial to see if a popular weight loss drug can help curb alcohol cravings<\/u><\/a>.
Clinicians are partnering with the pharmaceutical company Eli Lilly to test a new GLP-1 medication called brenipatide to see if it can effectively treat alcohol addiction. The trial is specifically assessing if it helps individuals with moderate to severe alcohol use disorder reduce their drinking or stop altogether.
This drug is similar to medications like Ozempic that can help with weight loss and diabetes. This trial will span 14 months. Participants will be between 18 and 75 years old. Across the U.S. 30 test sites that are participating in the drug trial. UW is the only one located in the Pacific Northwest.
Dr. Mark Duncan is a psychiatrist who specializes in addiction and is UW\u2019s principal investigator for the study.
He said this type of medication is well known for reducing food cravings, but there is emerging evidence that it helps with drinking and other addictive substances.
\u201cWhat you\u2019ll hear is that \u2018I just was not interested in drinking. I may have forgotten that I was typically drunk at this time\u2019 because all of the internal cues, and psychological cues, that you know are normally there are just not happening.\u201d
Duncan said if GLP-1s are proven to be an effective treatment for alcohol addiction this could be a huge step forward because many of the medications currently available aren\u2019t very consistent.
\u201cMeds for alcohol use disorder, they’re just not consistently effective,\u201d he said. \u201cWe really don’t have a good idea of why that is.\u201d
Mary Hatch, a psychologist with UW working on the drug trial, said using GLP-1 to help treat alcohol addiction is an exciting prospect.
\u201cThe possibility that your primary care provider could offer a medication that everybody has heard of, and that’s used for non-substance problems, like diabetes, or weight loss, or cardiac problems,\u201d she said, could make treatment more accessible.
She pointed out that other addiction treatment like rehab is not always appealing or easy to enroll in, and an effective medication could help more people who are struggling with their drinking.
Potentially, instead of signing up for inpatient rehab, \u201cI can just go to my regular doctor and get this regular medication,\u201d Hatch said.
According to a UW news release, this research is being conducted alongside other studies that are looking into whether this medication can help with opioid and nicotine addiction.
Get the latest updates on the international championship games from KNKX & NPR.
Get the latest news, music and events of the week, directly to your inbox<\/i>.<\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Researchers at the University of Washington are joining an international drug trial to see if a popular weight loss drug can help curb alcohol cravings.Clinicians are partnering with the pharmaceutical company Eli Lilly to test a new GLP-1 medication called brenipatide to see if it can effectively treat alcohol addiction. The trial is specifically assessing […]<\/p>\n","protected":false},"author":1,"featured_media":23866,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-23865","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health"],"_links":{"self":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/23865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/comments?post=23865"}],"version-history":[{"count":0,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/23865\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media\/23866"}],"wp:attachment":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media?parent=23865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/categories?post=23865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/tags?post=23865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}